EW

AI Research

Edwards Lifesciences Q4 EPS $0.58 Misses → 2026 EPS Guided $2.75, Structural Heart Focus

Edwards Lifesciences reported Q4 2025 EPS of $0.58, which fell short of analyst estimates, though the company provided 2026 EPS guidance of $2.75 as it refocuses exclusively on its structural heart disease business following recent divestitures. Analysts maintain a Buy consensus with an average price target of $87.06, reflecting long-term confidence in the company's TAVR leadership position and the large untreated structural heart disease patient population. Risks include slower-than-expected TAVR market penetration, emerging competitive pressure from transcatheter mitral and tricuspid solutions, and reimbursement headwinds in international markets.